BioChemics Collaborates With Unilever

BioChemics has signed a research collaboration agreement with Unilever to utilize its proprietary topical delivery technology for the delivery of Unilever’s compounds.

John Masiz, president and chief executive officer of BioChemics, said: “We are delighted to be working with Unilever to evaluate the broader applications of our technology for their products.

“In addition to our other ongoing collaborations, this agreement further validates the impact for our proprietary topical technology, making us attractive to a wide variety of partners to develop well-differentiated, cost-effective products for consumers.”

BioChemics is a pharmaceutical company that has developed a novel, transdermal drug delivery system that may allow almost any drug to be delivered through the skin.

The transdermal technology, VALE (Vaso-active Lipid Encapsulated), may allow a substantial portion of the pharmacopeia to be re-engineered, turning oral drugs into transdermals that are safer (no gastro-intestinal problems), cheaper and potentially faster acting (applied directly to the treated area) than oral equivalents, claims the company.